Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02937558 · ClinicalTrials.gov registry record · Phase 2
CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism
A Phase 2 study, sponsored by Xeris Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02937558 is a Phase 2 study that has completed, run by Xeris Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT02937558, a Phase 2 study, has completed, sponsored by Xeris Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children \< 1 year of age with congenital hyperinsulinism.
Interventions
- OTHER Placebo
- DRUG Glucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02937558
The ClinicalTrials.gov registry entry for NCT02937558 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xeris Pharmaceuticals, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02937558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02937558 about?
NCT02937558 is a clinical study titled "CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism". This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children \< 1 year ...
What is the current status of trial NCT02937558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2016-10. Estimated completion is 2018-10.
What interventions are being tested in trial NCT02937558?
The interventions under investigation include: Placebo (OTHER), Glucagon (DRUG).
Who is sponsoring clinical trial NCT02937558?
This trial is sponsored by Xeris Pharmaceuticals, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.